FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3152109309> ?p ?o ?g. }

• W3152109309 endingPage "2138" @default.
• W3152109309 startingPage "2131" @default.
• W3152109309 abstract "Drug resistance caused by G1202R/G1202del mutation in anaplastic lymphoma kinase (ALK) represents a great challenge in the clinic. The effect of other mutation(s) at G1202 on the available tyrosine kinase inhibitors (TKIs) in the clinic remains unknown.A 50-year-old Chinese male non-smoker with lung adenocarcinoma progressed with spinal metastasis after receiving chest radiation together with Pemetrexed and Cisplatin as adjuvant chemotherapy. Targeted next generation sequencing (NGS) identified EML4-ALK gene fusion in the resected left lung tissue. Local radiation followed by Crizotinib were used in the following treatment and the spinal metastasis was found to shrink, but the progression free survival (PFS) only lasted for 2 months with the appearance of brain metastasis. Afterwards, the patient benefited from the therapy of Alectinib with a PFS of 8 months. Then he progressed with metastases in right lung and pleural, and did not show response to the chemotherapy with Docetaxel plus Bevacizumab. The targeted sequencing consistently identified EML4-ALK gene fusion in both plasma and pleural effusion (PE), as well as a novel ALK G1202K mutation (c.3604_3605delGGinsAA). Given the lack of established or known drug treatment for this novel mutation, we implemented molecular dynamics (MD) simulation-guided drug sensitivity prediction, which results suggested Lorlatinib remains potent against G1202K mutant ALK. Therefore, Lorlatinib was used as the fourth-line therapy, which lead to the considerable efficacy with improved performance status (PS) score and reduced lung metastases. The structural mechanism underlying G1202K-induced drug resistance to different ALK-TKIs was also discussed.Our case suggested the ALK-G1202K mutation may serve as a novel mechanism underlying the resistance to Alectinib, and provide direct evidence to support its sensitization to Lorlatinib. Our work represented an example of integrating in silico predictions into clinical practice." @default.
• W3152109309 created "2021-04-13" @default.
• W3152109309 creator A5003742311 @default.
• W3152109309 creator A5020482090 @default.
• W3152109309 creator A5032428632 @default.
• W3152109309 creator A5033599023 @default.
• W3152109309 creator A5044757881 @default.
• W3152109309 creator A5045206097 @default.
• W3152109309 creator A5048841778 @default.
• W3152109309 creator A5061451649 @default.
• W3152109309 creator A5085880746 @default.
• W3152109309 creator A5086572452 @default.
• W3152109309 creator A5089694500 @default.
• W3152109309 date "2021-03-01" @default.
• W3152109309 modified "2023-10-12" @default.
• W3152109309 title "Identification of Novel Alectinib-Resistant ALK Mutation G1202K with Sensitization to Lorlatinib: A Case Report and in silico Structural Modelling" @default.
• W3152109309 cites W1975580333 @default.
• W3152109309 cites W1984068087 @default.
• W3152109309 cites W1997476230 @default.
• W3152109309 cites W2042694699 @default.
• W3152109309 cites W2055402151 @default.
• W3152109309 cites W2065283382 @default.
• W3152109309 cites W2067299919 @default.
• W3152109309 cites W2099530756 @default.
• W3152109309 cites W2103110584 @default.
• W3152109309 cites W2103441770 @default.
• W3152109309 cites W2118233996 @default.
• W3152109309 cites W2119180969 @default.
• W3152109309 cites W2155943701 @default.
• W3152109309 cites W2205667543 @default.
• W3152109309 cites W2293213775 @default.
• W3152109309 cites W2319183095 @default.
• W3152109309 cites W2405792137 @default.
• W3152109309 cites W2482427906 @default.
• W3152109309 cites W2581592505 @default.
• W3152109309 cites W2617304980 @default.
• W3152109309 cites W2791498761 @default.
• W3152109309 cites W2901525385 @default.
• W3152109309 cites W2903836900 @default.
• W3152109309 cites W2911858378 @default.
• W3152109309 cites W2942945599 @default.
• W3152109309 cites W2951718918 @default.
• W3152109309 cites W2967710850 @default.
• W3152109309 cites W2982257091 @default.
• W3152109309 cites W3027882342 @default.
• W3152109309 doi "https://doi.org/10.2147/ott.s293901" @default.
• W3152109309 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8007639" @default.
• W3152109309 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33790576" @default.
• W3152109309 hasPublicationYear "2021" @default.
• W3152109309 type Work @default.
• W3152109309 sameAs 3152109309 @default.
• W3152109309 citedByCount "6" @default.
• W3152109309 countsByYear W31521093092021 @default.
• W3152109309 countsByYear W31521093092022 @default.
• W3152109309 countsByYear W31521093092023 @default.
• W3152109309 crossrefType "journal-article" @default.
• W3152109309 hasAuthorship W3152109309A5003742311 @default.
• W3152109309 hasAuthorship W3152109309A5020482090 @default.
• W3152109309 hasAuthorship W3152109309A5032428632 @default.
• W3152109309 hasAuthorship W3152109309A5033599023 @default.
• W3152109309 hasAuthorship W3152109309A5044757881 @default.
• W3152109309 hasAuthorship W3152109309A5045206097 @default.
• W3152109309 hasAuthorship W3152109309A5048841778 @default.
• W3152109309 hasAuthorship W3152109309A5061451649 @default.
• W3152109309 hasAuthorship W3152109309A5085880746 @default.
• W3152109309 hasAuthorship W3152109309A5086572452 @default.
• W3152109309 hasAuthorship W3152109309A5089694500 @default.
• W3152109309 hasBestOaLocation W31521093091 @default.
• W3152109309 hasConcept C117643217 @default.
• W3152109309 hasConcept C121608353 @default.
• W3152109309 hasConcept C126322002 @default.
• W3152109309 hasConcept C143998085 @default.
• W3152109309 hasConcept C2776232967 @default.
• W3152109309 hasConcept C2776256026 @default.
• W3152109309 hasConcept C2776694085 @default.
• W3152109309 hasConcept C2777240266 @default.
• W3152109309 hasConcept C2778164965 @default.
• W3152109309 hasConcept C2778239845 @default.
• W3152109309 hasConcept C2778820342 @default.
• W3152109309 hasConcept C2779013556 @default.
• W3152109309 hasConcept C2779220645 @default.
• W3152109309 hasConcept C2779422266 @default.
• W3152109309 hasConcept C2781230642 @default.
• W3152109309 hasConcept C502942594 @default.
• W3152109309 hasConcept C71924100 @default.
• W3152109309 hasConceptScore W3152109309C117643217 @default.
• W3152109309 hasConceptScore W3152109309C121608353 @default.
• W3152109309 hasConceptScore W3152109309C126322002 @default.
• W3152109309 hasConceptScore W3152109309C143998085 @default.
• W3152109309 hasConceptScore W3152109309C2776232967 @default.
• W3152109309 hasConceptScore W3152109309C2776256026 @default.
• W3152109309 hasConceptScore W3152109309C2776694085 @default.
• W3152109309 hasConceptScore W3152109309C2777240266 @default.
• W3152109309 hasConceptScore W3152109309C2778164965 @default.
• W3152109309 hasConceptScore W3152109309C2778239845 @default.
• W3152109309 hasConceptScore W3152109309C2778820342 @default.
• W3152109309 hasConceptScore W3152109309C2779013556 @default.
• W3152109309 hasConceptScore W3152109309C2779220645 @default.

• next